Abstract 2319P
Background
Drug therapy is an essential component of cancer treatment. Accurate drug sensitivity analysis can help healthcare professionals determine the right drugs to use, leading to improved patient outcomes and quality of life. However, a lack of web-based tools with robust visualization and analysis capabilities for pan-cancer drug sensitivity remains a challenge.
Methods
To address this gap, we developed the Comprehensive Analysis of Drug Sensitivity in Pan-cancer (CADSP), a Shiny-based web tool. We collected oncology drug sensitivity-related data from large publicly available databases, including Gene Expression Omnibus (GEO), The Cancer Genome Atlas Program (TCGA), and Drug Sensitivity in Cancer (GDSC).
Results
The current version of CADSP includes transcriptomic data for over 29,000 samples, covering 44 cancer types, 288 drugs, and more than 9,000 gene perturbation data. Users can easily perform various tumor drug sensitivity analyses using CADSP. The tool provides numerous analysis and visualization methods, such as differential gene analysis, gene correlation analysis, pathway analysis, drug analysis, and gene perturbation analysis. Table: 2319P
Comparison of CADSP with other anti-tumor drug sensitivity analysis web server
CADSP | canSAR | CellMiner | GSCALite | PharmacoDB | DRESIS | |
Dataset | TCGA, GDSC, GEO(including NCI-60), GPSAdb | TCGA, ICGC | GDSC, CCLE, CTRP, NCI-60 | GDSC, TCGA, GTEx | NCI-60, GDSC, PRISM, CCLE, gCSI | DrugBank, CCNSC, TTD |
Sample | ∼29,000 | ∼25,000 | 1,400 | 23,594 | 1,757 | - |
Cancer types | 44 | 26 | 60 | 33 | 30 | 125 |
Analysis module | ①Differential expression gene analysis ②Correlation analysis ③Pathway analysis(GSEA, ssGSEA, Pathview) ④Drug analysis ⑤Genetic perturbations | Genomic data analysis | Correlation analysis | ①Genomic data analysis ②Pathway activity ③miRNA network ④Drug sensitivity | ①Genomic data analysis ②Correlation analysis ③Drug sensitivity | Resistance mechanisms analysis |
Parameters customization | ✓ | ✕ | ✕ | ✕ | ✕ | ✕ |
Conclusions
CADSP greatly simplifies the exploration of primary and secondary drug resistance at the single-gene and pathway levels for physicians and researchers. By combining drug resistance data and gene perturbation data, CADSP also offers new avenues for discovering key genes that drive drug resistance. CADSP is available at https://smuonco.shinyapps.io/CADSP/.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The Natural Science Foundation of Guangdong Province [2018A030313846, 2021A1515012593]; the Science and Technology Planning Project of Guangdong Province [2019A030317020]; the National Natural Science Foundation of China [81802257, 81871859, 81772457, 82172750 and 82172811]; and the Guangdong Basic and Applied Basic Research Foundation (Guangdong - Guangzhou Joint Funds) [2022A1515111212].
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2262P - Baseline-informed versus tumor-agnostic minimal residual disease (MRD) concordance study in patients with HER2+ gastroesophageal adenocarcinoma patients
Presenter: Pan Du
Session: Poster session 08
2263P - Ethnicity-specific distribution of BRCA1, BRCA2, PALB2 and ATM pathogenic alleles in breast and ovarian cancer patients from the North Caucasus
Presenter: Evgeny Imyanitov
Session: Poster session 08
2264P - Proteomics-based phenotypic classification of non-smallcell lung cancer
Presenter: Olena Berkovska
Session: Poster session 08
2265P - miR-4487 enhances gefitinib-mediated ubiquitination and autophagic degradation of EGFR in non-small cell lung cancer cells by targeting USP37
Presenter: Sei-Hoon Yang
Session: Poster session 08
2266P - IMMUcan consortium: Focus on the first results of the non-small cell lung cancer (NSCLC) cohort
Presenter: Marie Morfouace
Session: Poster session 08
2267P - Coronary heart disease and risk of lung cancer: A two-sample Mendelian randomization study
Presenter: Cai Chen Li
Session: Poster session 08
2269P - Patient derived xenografts generated from circulating cancer stem cells on chorioallantoic membrane as an alternative pre-clinical model for personalized medicine in pancreatic cancer
Presenter: Monika Pizon
Session: Poster session 08
2270P - Integrative analyses of bulk and single-cell RNA-seq identified diabetes mellitus-related signature as a prognostic factor in pancreatic adenocarcinoma
Presenter: Le Tang
Session: Poster session 08
2271P - Development of an oncolytic virus for the treatment of high grade serous ovarian cancer and other stromal rich tumours
Presenter: Miriam Bazan Peregrino
Session: Poster session 08
2272P - Minimal DNA-methylation (DNAm) signatures for non-invasive tumor-agnostic estimation of tumor content (TC) and molecular subtype in patients (pts) with metastatic breast cancer (mBC)
Presenter: Matteo Benelli
Session: Poster session 08